Astana Biomed Group, an authorized Abcam distributor in Central Asia

Anti-Liver Arginase antibody [EPR6672(B)] - BSA and Azide free (ab211961)

Key features and details

  • Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
  • Rabbit monoclonal [EPR6672(B)] to Liver Arginase - BSA and Azide free
  • Suitable for: IHC-P, WB, IP
  • Reacts with: Human

Overview

  • Product name

    Anti-Liver Arginase antibody [EPR6672(B)] - BSA and Azide free
    See all Liver Arginase primary antibodies

  • Description

    Rabbit monoclonal [EPR6672(B)] to Liver Arginase - BSA and Azide free

  • Host species

    Rabbit

  • Tested applications

    Suitable for: IHC-P, WB, IPmore details

  • Species reactivity

    Reacts with: Human

  • Immunogen

    Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.

  • Positive control

    • Human fetal liver and Human fetal lung lysates; Human hepatocellular carcinoma tissue.

  • General notes

    Ab211961 is the carrier-free version of ab133543. This format is designed for use in antibody labeling, including fluorochromes, metal isotopes, oligonucleotides, enzymes.

     

    Our carrier-free formats are supplied in a buffer free of BSA, sodium azide and glycerol for higher conjugation efficiency.

    Use our conjugation kits  for antibody conjugates that are ready-to-use in as little as 20 minutes with

    ab211961 is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm.

    Maxpar® is a trademark of Fluidigm Canada Inc.

    This product is a recombinant monoclonal antibody, which offers several advantages including:

    • - High batch-to-batch consistency and reproducibility
    • - Improved sensitivity and specificity
    • - Long-term security of supply
    • - Animal-free production
    For more information see here.

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

Properties

Images

  • Immunoprecipitation - Anti-Liver Arginase antibody [EPR6672(B)] - BSA and Azide free (ab211961)
    Immunoprecipitation - Anti-Liver Arginase antibody [EPR6672(B)] - BSA and Azide free (ab211961)

    Lane 1 (input): Human fetal liver whole cell lysate, 10μg
    Lane 2: Human fetal liver whole cell lysate
    Lane 3: Rabbit monoclonal IgG (ab172730) instead of ab133543 in Human fetal liver whole cell lysate

    Ab133543 immunoprecipitating liver arginase in Human fetal liver whole cell lysates. Primary antibody was used at a 1:1000 dilution (0.27 μg/ml). For western blotting, VeriBlot for IP Detection Reagent (HRP) (ab131366), was used for detection at 1/5000 dilution.  Capture antibody was used at 1:20 dilution (1.3μg in 0.35mg lysates).

    Blocking and diluting buffer used: 5% NFDM/TBST.

    This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab133543).

  • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Liver Arginase antibody [EPR6672(B)] - BSA and Azide free (ab211961)
    Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Liver Arginase antibody [EPR6672(B)] - BSA and Azide free (ab211961)

    This IHC data was generated using the same anti-Liver Arginase antibody clone, EPR6672(B), in a different buffer formulation (cat# ab133543).

    Immunohistochemical analysis of paraffin embedded Human hepatocellular carcinoma tissue labelling liver Arginase with ab133543 antibody at a dilution of 1/250.

  • Anti-Liver Arginase antibody [EPR6672(B)] - BSA and Azide free (ab211961)
    Anti-Liver Arginase antibody [EPR6672(B)] - BSA and Azide free (ab211961)

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Alternative products to Anti-Liver Arginase antibody [EPR6672(B)] - BSA and Azide free (ab211961)

© 2021 Astana Biomed Group LLP. All rights reserved.